Changes in adiponectin level and fat distribution in patients with type 2 diabetes

Miazgowski, Tomasz; Dziwura-Ogonowska, Joanna; Safranow, Krzysztof; Iskierska, Katarzyna; Widecka, Krystyna

doi:10.1111/eci.12207

Cited by 11 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in T2DM (46). Studies reporting decreased adiponectin levels in T2DM in adults (17,24,47,48) or children (15,18,(31)(32)(33)(34)49) were based on normal weight controls and not age-, gender-, and BMI-matched controls as in our study explaining the difference to our study.…”

Section: Discussioncontrasting

confidence: 89%

Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents

et al. 2015

View full text Add to dashboard Cite

Because adiponectin levels did not differ between obese adolescents with and without T2DM, hypoadiponectinemia as observed in obesity seems not to be involved in the genesis of T2DM. The relative hypoleptinemia in obese adolescents with T2DM as compared with obese adolescents without T2DM may contribute to the development of T2DM. Future longitudinal studies in humans are necessary to prove this hypothesis.

show abstract

Section: Discussioncontrasting

confidence: 89%

Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents

et al. 2015

View full text Add to dashboard Cite

show abstract

“…With rosiglitazone treatment at 4 or 8 mg/day, adiponectin levels increase by ∼50–200% after 3–6 months in adults with type 2 diabetes, with improvements in glycemic control and insulin sensitivity (30–32). With respect to metformin treatment in adults with type 2 diabetes, most studies (33,34)—but not all (35,36)—show no change in adiponectin levels. In the Diabetes Prevention Program (DPP), however, metformin intervention in impaired glucose tolerant adults was associated with a significant increase in adiponectin from baseline to year 1 (24).…”

Section: Discussionmentioning

confidence: 95%

Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY

et al. 2016

View full text Add to dashboard Cite

OBJECTIVEThe Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined—metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle—were higher in non-Hispanic blacks (NHB; 52.8%) versus non-Hispanic whites (NHW; 36.6%) and Hispanics (H; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity.RESEARCH DESIGN AND METHODSTODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA).RESULTSAt baseline NHB had significantly lower HMWA than NHW and H and exhibited a significantly smaller increase (17.3% vs. 33.7% vs. 29.9%, respectively) during the first 6 months overall. Increases in HMWA were associated with reductions in glycemic failure in the three racial/ethnic groups combined (hazard ratio 0.61, P < 0.0001) and in each race/ethnicity separately. Over time, HMWA was significantly lower in those who failed versus did not fail treatment, irrespective of race/ethnicity. There were no differences in treatment-associated temporal changes in insulin sensitivity, C-peptide index, and oDI among the three racial/ethnic groups.CONCLUSIONSHMWA is a reliable biomarker of treatment response in youth with type 2 diabetes. The diminutive treatment-associated increase in HMWA in NHB (∼50% lower) compared with NHW and H may explain the observed racial/ethnic disparity with higher therapeutic failure rates in NHB in TODAY.

show abstract

“…It is also very interesting to find that type 2 diabetics show a significantly decreased irisin level compared with control and PCOS subjects when exclude androgen‐driven lean mass factor. Type 2 diabetes is linked to more visceral fat, less thigh subcutaneous fat and more fat infiltration in muscle compared with persons without diabetes . Certainly, we should do more exploring on these primary results.…”

Section: Discussionmentioning

confidence: 98%

The relationships of irisin with bone mineral density and body composition in PCOS patients

Gao

Cheng

Zhao

et al. 2016

Diabetes Metabolism Res

View full text Add to dashboard Cite

Objective Our study aims to assay the irisin level and investigate the relationships of irisin level with body mass index (BMI), body composition and bone metabolism in the polycystic ovary syndrome (PCOS) and control women.Methods Fifty two PCOS and 39 control women were recruited. Serum sex hormone, fasting insulin and C-peptide were tested. Fasting serum irisin and adiponectin were measured with enzyme-linked immunosorbent assay. Body composition and bone mineral density were assayed by dual energy X-ray absorptiometry.Results Polycystic ovary syndrome women showed different body compositions compared with controls. Serum irisin level of PCOS did not show significant difference compared with controls although it was decreased. The level of adiponectin in PCOS patients was significantly reduced. BMI had no correlation with irisin level. It indicated a positive correlation between serum irisin levels and bone mineral density in the control group and a negative correlation in the PCOS group after BMI and age adjusted. Furthermore, total lean mass has a significant effect on irisin concentration in the PCOS group. There are no correlations between adiponection and body compositions and bone mineral density in both groups.Conclusions The abnormal body composition in PCOS may contribute to the circulation irisin. The crosstalk of irisin in different organs was found and may be related to disease development in PCOS.

show abstract

Changes in adiponectin level and fat distribution in patients with type 2 diabetes

Abstract: In postmenopausal women with newly diagnosed T2DM, lifestyle modifications alone or combined with metformin produced comparable changes in adiponectin levels. Weight reduction in patients treated with metformin was associated with significant decrease in %BF but not in regional fat depots.

Cited by 11 publications

References 37 publications

Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents

Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents

Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY

The relationships of irisin with bone mineral density and body composition in PCOS patients

Contact Info

Product

Resources

About